Yr Athro Richard Adams

2021

• Cohen, R.et al. 2021. BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. JNCI: Journal of the National Cancer Institute 113(10), pp. 1386–1395-1395. (10.1093/jnci/djab042)
• Seligmann, J. F.et al. 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology (10.1200/JCO.21.01435)
• Adams, R. A.et al. 2021. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology (10.1200/JCO.21.01436)
• Adams, R.et al. 2021. Treatment breaks in first line treatment of advanced colorectal cancer: an individual patient data meta-analysis. Cancer Treatment Reviews 99, article number: 102226. (10.1016/j.ctrv.2021.102226)
• ten Hoorn, S.et al. 2021. Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer (10.1038/s41416-021-01477-9)
• RECOVERY Collaborative Group, . and Adams, R. 2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet 397(10289), pp. 2049-2059. (10.1016/s0140-6736(21)00897-7)
• Abani, O.et al. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397(10285), pp. 1637-1645. (10.1016/S0140-6736(21)00676-0)
• Hanna, C.et al. 2021. Intensity-modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology 33(4), pp. 214-223. (10.1016/j.clon.2020.12.011)
• Clifford, R. E.et al. 2021. Rectal cancer management during the COVID-19 pandemic (ReCaP): multicentre prospective observational study. British Journal of Surgery, article number: znab129. (10.1093/bjs/znab129)
• Bach, S. P.et al. 2021. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterology and Hepatology 6(2), pp. 92-105. (10.1016/S2468-1253(20)30333-2)
• Horby, P.et al. 2021. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 384(8), pp. 693-704. (10.1056/NEJMoa2021436)
• Abaleke, E.et al. 2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397(10274), pp. 605-612. (10.1016/S0140-6736(21)00149-5)
• Yin, J.et al. 2021. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology 13, pp. 1-11. (10.1177/17588359211020547)

2020

• Horby, P.et al. 2020. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine 383(21), pp. 2030-2040. (10.1056/NEJMoa2022926)
• Glynne-Jones, R.et al. 2020. Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. Annals of Oncology 31(11), pp. 1587-1588. (10.1016/j.annonc.2020.08.2097)
• Glynne-Jones, R.et al. 2020. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Annals of Oncology 31(10), pp. 1376-1385. (10.1016/j.annonc.2020.06.012)
• Germetaki, T.et al. 2020. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncology 16(28), pp. 2177-2189. (10.2217/fon-2020-0523)
• Barber, P. R.et al. 2020. HER2-HER3 heterodimer quantification by FRET-FILM and patient subclass analysis of the COIN colorectal trial. JNCI: Journal of the National Cancer Institute 112(9), pp. 944-954. (10.1093/jnci/djz231)
• Karapetis, C. S.et al. 2020. 434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database. Annals of Oncology 31(S4), article number: S426. (10.1016/j.annonc.2020.08.545)
• Papamichael, D.et al. 2020. 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database. Annals of Oncology 31, article number: S425. (10.1016/j.annonc.2020.08.543)
• Rao, S.et al. 2020. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil cersus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology 38(22), pp. 2510-2518. (10.1200/JCO.19.03266)
• O'Cathail, S. M.et al. 2020. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology 15, article number: 151. (10.1186/s13014-020-01593-5)
• Forde, C.et al. 2020. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials 21, article number: 431. (10.1186/s13063-020-04241-1)
• Gilbert, A.et al. 2020. UK national cohort of anal cancer treated with intensity-modulated radiotherapy: one-year oncological and patient-reported outcomes. European Journal of Cancer 128, pp. 7-16. (10.1016/j.ejca.2019.12.022)
• Chalmers, A.et al. 2020. CTRad 10 years on: from 10-point plan to top 10 achievements. Clinical Oncology 32(1), pp. 9-12. (10.1016/j.clon.2019.09.043)

2019

• Joharatnam-Hogan, N.et al. 2019. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology 4(11), pp. 854-862. (10.1016/S2468-1253(19)30289-4)
• Gilbert, A.et al. 2019. 535P - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5). Annals of Oncology 30(S5), pp. v203-v204. (10.1093/annonc/mdz246.013)
• Vallance, A.et al. 2019. Making an IMPACT: A priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer. EJSO - European Journal of Surgical Oncology 45(9), pp. 1467-1574. (10.1016/j.ejso.2019.04.005)
• Renehan, A.et al. 2019. Early stage anal margin cancer: towards evidence‐based management. Colorectal Disease 21(4), pp. 387-391. (10.1111/codi.14571)

2018

• Fish, R.et al. 2018. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterology and Hepatology 3(12), pp. 865-873. (10.1016/S2468-1253(18)30264-4)
• West, H.et al. 2018. Role for nucleotide excision repair gene variants in oxaliplatin-induced peripheral neuropathy. JCO Precision Oncology 2, pp. 1-18. (10.1200/PO.18.00090)
• Salem, M. E.et al. 2018. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. European Journal of Cancer 103, pp. 205-213. (10.1016/j.ejca.2018.08.020)
• Cross, W.et al. 2018. The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution 2(10), pp. 1661-1672. (10.1038/s41559-018-0642-z)
• Elwood, P.et al. 2018. Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. PLoS ONE 13(9), pp. e0203957. (10.1371/journal.pone.0203957)
• Madi, A.et al. 2018. Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII22., (10.1093/annonc/mdy269.072)
• Rao, S.et al. 2018. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018, Vol. 29. Vol. Supple. Oxford University Press pp. VIII715-VIII716., (10.1093/annonc/mdy424.022)
• Madi, A.et al. 2018. Pharmacogenetic analyses of 2,183 patients with advanced colorectal cancer; Potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.. European Journal of Cancer 102, pp. 31-39. (10.1016/j.ejca.2018.07.009)
• Goey, K. K.et al. 2018. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer 100, pp. 35-45. (10.1016/j.ejca.2018.05.010)
• Gollins, S.et al. 2018. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer (10.1038/s41416-018-0209-4)
• Jones, C. M.et al. 2018. Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort. International Journal of Radiation Oncology - Biology - Physics 101(5), pp. 1202-1211. (10.1016/j.ijrobp.2018.04.033)
• Sjoquist, K. M.et al. 2018. Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project. JNCI: Journal of the National Cancer Institute 110(6), pp. 638-648. (10.1093/jnci/djx253)
• Rose, G.et al. 2018. The cardiopulmonary exercise test grey zone; optimising fitness stratification by application of critical difference. British Journal of Anaesthesia 120(6), pp. 1187-1194. (10.1016/j.bja.2018.02.062)
• Bhoday, J.et al. 2018. Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. Presented at: Future Horizons International Experts Meeting in Colorectal Cancer 2015, London, England, 25 June 2015 Presented at Wale, A. and Brown, G. eds., Vol. 20. Vol. S`. Wiley pp. 97-99., (10.1111/codi.14088)
• Alderdice, M.et al. 2018. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. The Journal of Pathology 245(1), pp. 19-28. (10.1002/path.5051)
• Adams, R.et al. 2018. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2?3 randomised trial. Lancet Gastroenterology and Hepatology 3(3), pp. 162-171. (10.1016/S2468-1253(17)30394-1)
• Lawler, M.et al. 2018. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut 67(1), pp. 179-193. (10.1136/gutjnl-2017-315333)
• Elwood, P.et al. 2018. Healthy living and cancer: evidence from UK Biobank. ecancermedicalscience 12, article number: 792. (10.3332/ecancer.2018.792)

2017

• Scurr, M.et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
• Wasan, H. S.et al. 2017. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology 18(9), pp. 1159-1171. (10.1016/S1470-2045(17)30457-6)
• Scurr, M. J.et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
• Battersby, N. J.et al. 2017. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials 18, article number: 394. (10.1186/s13063-017-2085-2)
• Geh, I.et al. 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management ofcancer of the Colon, rectum and anus (2017) - anal cancer. Colorectal Disease 19(S1), pp. 82-97. (10.1111/codi.13709)
• Gollins, S.et al. 2017. Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017) - multidisciplinary management. Colorectal Disease 19(S1), pp. 37-66. (10.1111/codi.13705)
• Lal, N.et al. 2017. Endothelial protein C receptor is overexpressed in colorectal cancer as a result of amplification and hypomethylation of chromosome 20q. The Journal of Pathology: Clinical Research 3(3), pp. 155-170. (10.1002/cjp2.70)
• Hendry, M.et al. 2017. Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open 7(6), article number: e015413. (10.1136/bmjopen-2016-015413)
• Renfro, L. A.et al. 2017. Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the Aide et Recherche en Cancérologie digestive database. Journal of Clinical Oncology 35(17), pp. 1929-1937. (10.1200/JCO.2016.71.5771)
• Glynne-Jones, R.et al. 2017. Clinical endpoints in trials of chemoradiation for patients with anal cancer. Lancet Oncology 18(4), pp. e218-e227. (10.1016/S1470-2045(17)30190-0)
• Madi, A.et al. 2017. Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. Journal of Medical Genetics 54(8), pp. 567-571. (10.1136/jmedgenet-2016-104317)
• Seligmann, J.et al. 2017. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology 28(3), pp. 562-568. (10.1093/annonc/mdw645)
• Scurr, M.et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
• Adams, R. 2017. Surveillance of anal canal cancers. Surgical Oncology Clinics of North America 26(1), pp. 127-132. (10.1016/j.soc.2016.07.007)
• Wood, G.et al. 2017. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status. Anti-Cancer Drugs 28(5), pp. 546-550. (10.1097/CAD.0000000000000488)

2016

• Franko, J.et al. 2016. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology 17(12), pp. 1709-1719. (10.1016/S1470-2045(16)30500-9)
• Taylor, S.et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28(10), pp. e139-e147. (10.1016/j.clon.2016.06.004)
• Muirhead, R.et al. 2016. Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015. Clinical Oncology 29(3), pp. 188-197. (10.1016/j.clon.2016.10.005)
• Gilbert, D.et al. 2016. Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: from consensus guidance to large-scale prospective audit, prior to future clinical trials. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, USA, 25-28 September 2016, Vol. 96. Vol. 2. Elsevier pp. S105-S106., (10.1016/j.ijrobp.2016.06.260)
• Sebag-Montefiore, D.et al. 2016. The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus. Presented at: 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA, USA, 25-28 September 2016, Vol. 96. Vol. 2. Elsevier pp. E164-E165., (10.1016/j.ijrobp.2016.06.1006)
• Weber, A. M.et al. 2016. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. Oncotarget 7(38), pp. 60807-60822. (10.18632/oncotarget.11845)
• Sharma, R. A.et al. 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13, pp. 627-642. (10.1038/nrclinonc.2016.79)
• Hendry, M.et al. 2016. Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open 6(4), article number: e011205. (10.1136/bmjopen-2016-011205)
• Ciardiello, F.et al. 2016. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. The Oncologist 21(3), pp. 292-300. (10.1634/theoncologist.2015-0279)
• Morris, E. J. A.et al. 2016. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clinical Oncology 28(8), pp. 522-531. (10.1016/j.clon.2016.02.002)
• Grenader, T.et al. 2016. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. British Journal of Cancer 114(6), pp. 612-615. (10.1038/bjc.2016.23)
• Renfro, L. A.et al. 2016. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. Journal of Clinical Oncology 34(2), pp. 144-150. (10.1200/JCO.2015.61.6441)
• Hubbard, G.et al. 2016. Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study. BMJ Open 6(1), article number: e009284. (10.1136/bmjopen-2015-009284)

2015

• Richman, S. D.et al. 2015. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology 69(1), pp. 35-41. (10.1136/jclinpath-2015-203097)
• Hutchinson, R. A.et al. 2015. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. Journal of Translational Medicine 13, article number: 217. (10.1186/s12967-015-0531-z)
• Shi, Q.et al. 2015. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. Journal of Clinical Oncology 33(1), pp. 22-28. (10.1200/JCO.2014.56.5887)

2014

• Baillie, J.et al. 2014. Developing meaningful public involvement in a cancer clinical trials unit. Presented at: COMET IV Meeting: Core Outcome Measures in Effectiveness Trials, Rome, Italy, 20-21 November 2014.
• Muirhead, R.et al. 2014. Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26(11), pp. 720-721. (10.1016/j.clon.2014.08.001)
• Barbieri, M.et al. 2014. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Applied Health Economics and Health Policy 12(5), pp. 497-510. (10.1007/s40258-014-0115-8)
• Muirhead, R.et al. 2014. Anal cancer: Developing an intensity-modulated radiotherapy solution for ACT2 fractionation. Clinical Oncology 26(11), pp. 720-721. (10.1016/j.clon.2014.08.001)
• Wasan, H.et al. 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. The Lancet Oncology 15(6), pp. 631-639. (10.1016/S1470-2045(14)70106-8)
• Glynne-Jones, R.et al. 2014. End points in anal cancer: hopes for a common language. Journal of Clinical Oncology 32(12), pp. 1281-1282. (10.1200/JCO.2014.55.1515)
• Glynne-Jones, R.et al. 2014. End points in anal cancer: Hopes for a common language. Journal of Clinical Oncology 32(12), pp. 1281-1282. (10.1200/JCO.2014.55.1515)
• Maughan, T.et al. 2014. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): A model for randomised controlled trials in the era of personalised medicine?. British Journal of Cancer 110, pp. 2178-2186. (10.1038/bjc.2014.182)
• Munro, J.et al. 2014. CRIB-the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4(2), article number: e004684. (10.1136/bmjopen-2013-004684)
• Munro, J.et al. 2014. CRIB - the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study. BMJ Open 4(2), article number: e004684. (10.1136/bmjopen-2013-004684)
• Adams, R. and Maughan, T. 2014. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Review of Anticancer Therapy 7(4), pp. 503-518. (10.1586/14737140.7.4.503)

2013

• Smith, C.et al. 2013. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clinical Cancer Research 19(15), pp. 4104-4113. (10.1158/1078-0432.CCR-12-2581)
• Smith, C.et al. 2013. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Human Mutation 34(7), pp. 1026-1034. (10.1002/humu.22333)
• Glynne-Jones, R.et al. 2013. Prognostic factors for recurrence and survival in anal cancer. Cancer 119(4), pp. 748-755. (10.1002/cncr.27825)
• Türbachova, I.et al. 2013. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics 8(11), pp. 1226-1235. (10.4161/epi.26334)

2012

• Vale, C. L.et al. 2012. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treatment Reviews 38(6), pp. 618-625. (10.1016/j.ctrv.2011.11.002)
• Madi, A.et al. 2012. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer 107(7), pp. 1037-1043. (10.1038/bjc.2012.384)
• Dunlop, M. G.et al. 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk [Letter]. Nature Genetics 44(7), pp. 770-776. (10.1038/ng.2293)
• Gwynne, S. H.et al. 2012. Image-guided radiotherapy for rectal cancer - A systematic review. Clinical Oncology 24(4), pp. 250-260. (10.1016/j.clon.2011.07.012)
• Gwynne, S.et al. 2012. Imaging for target volume delineation in rectal cancer radiotherapy - A systematic review. Clinical Oncology 24(1), pp. 52-63. (10.1016/j.clon.2011.10.001)

2011

• Glynne-Jones, R.et al. 2011. "Mind the gap" - The impact of variations in the duration of the treatment gap and overall treatment time in the first UK anal cancer trial (ACT I). International Journal of Radiation Oncology*Biology*Physics 81(5), pp. 1488-1494. (10.1016/j.ijrobp.2010.07.1995)
• Maughan, T. S.et al. 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet 377(9783), pp. 2103-2114. (10.1016/S0140-6736(11)60613-2)
• Adams, R. A.et al. 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet Oncology 12(7), pp. 642-653. (10.1016/S1470-2045(11)70102-4)
• Shaw, P. and Adams, R. A. 2011. Where now for anti-EGF receptor therapies in colorectal cancer?. Expert Review of Anticancer Therapy 11(10), pp. 1543-1553. (10.1586/era.11.143)

2010

• Maughan, T.et al. 2010. Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option [Letter]. Journal of Clinical Oncology 28(17), pp. e275-e276. (10.1200/JCO.2009.27.8218)

2009

• Adams, R., Maughan, T. and Crosby, T. 2009. Colon and rectum. In: Hanna, L., Crosby, T. and Macbeth, F. eds. Practical Clinical Oncology. Cambridge University Press, pp. 159-173., (10.1017/CBO9780511545375.014)
• Adams, R. A.et al. 2009. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. British Journal of Cancer 100(2), pp. 251-258. (10.1038/sj.bjc.6604877)
• Wadhawan, A., Stephens, R. and Adams, R. 2009. Intermittent therapy in the palliative treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 9(1), pp. 125-134. (10.1586/14737140.9.1.125)
• Morgan, M. A.et al. 2009. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. British Journal of Surgery 96(11), pp. 1300-1307. (10.1002/bjs.6705)
• Clements, D.et al. 2009. Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Disease 11(8), pp. 845-848. (10.1111/j.1463-1318.2008.01695.x)

2008

• Adams, R.et al. 2008. Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Review of Anticancer Therapy 8(8), pp. 1237-1245. (10.1586/14737140.8.8.1237)

2007

• Adams, R.et al. 2007. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. EJSO - European Journal of Surgical Oncology 33(3), pp. 307-313. (10.1016/j.ejso.2006.10.026)
• Shaw, P. H. S.et al. 2007. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clinical Oncology 19(1), pp. 87-95. (10.1016/j.clon.2006.09.009)

1993

• Hardie, K. R., Adams, R. A. and Towner, K. J. 1993. Transferrin-binding ability of invasive and commensal isolates of Haemophilus spp.. Journal of Medical Microbiology 39(3), pp. 218-224. (10.1099/00222615-39-3-218)